The following is a summary of “MicroRNA Regulation for Inflammasomes in High Glucose-Treated ARPE-19 Cells,” published in the August 2024 issue of Ophthalmology by Kim et al.
Researchers conducted a retrospective study to assess the expression of microRNAs (miRNAs) and inflammasomes in diabetes-induced retinal cells and to define the pathogenesis of diabetic retinopathy (DR).
They used diabetes-induced cell models by treating ARPE-19 cells with high glucose, and the expression levels of 5 miRNAs (miR-185, miR-17, miR-20a, miR-15a, and miR-15b) were estimated in these cells employing real-time quantitative polymerase chain reaction (RT-qPCR). Western blotting was conducted to evaluate inflammasome expression, miR-17 was picked as the target miRNA, and inflammasome expression was calculated after transfecting an miR-17 mimic into the high glucose-treated ARPE-19 cells.
The results showed a drop in miRNA expression in high glucose-treated ARPE-19 cells compared to high inflammasome levels. After transfecting the miR-17 mimic into high glucose-treated ARPE-19 cells, the levels of inflammasome components were comparatively reduced.
They concluded the relationship between miRNAs and inflammasomes in diabetes-induced cells using high glucose-treated ARPE-19 cells and suggested miR-17 suppressed inflammasomes, reduced the inflammatory response, and inflammasomes as a potential approach for DR.
Source: onlinelibrary.wiley.com/doi/full/10.1155/2024/3654690
The post Targeting miR-17 to Modulate Inflammasome Activity in Diabetic Cells first appeared on Physician's Weekly.